Clinical Trial Update: A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) [Phase 3]

View source ↗

Summary

Phase 3 trial RAP-MD-01 studied rapastinel as adjunctive therapy in major depressive disorder; trial completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Rapastinel (Rapastinel)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED | Results posted: 2019-10-11